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Open Forum Infectious Diseases
MAJOR ARTICLE

A Nonrestrictive Approach to Fluoroquinolone
Stewardship at Two Community Hospitals
William R. Truong,1,2 Philip A. Robinson,3 Richard C. Beuttler,2 and Jason Yamaki2,4
1

Background. Fluoroquinolones are one of the most prescribed antimicrobials in the United States and have been increasingly
used in inpatient and outpatient settings to treat various infectious diseases syndromes. Due to the unwanted collateral effects on
antibiotic resistance, poor susceptibility rates among Gram-negative pathogens, and adverse effects, fluoroquinolones are often
targeted by hospital antimicrobial stewardship programs to prevent overutilization. This study describes the association of
nonrestrictive antimicrobial stewardship interventions at 2 nonacademic community hospitals on levofloxacin utilization,
prescribing patterns on alternative antibiotics, and Pseudomonas aeruginosa nonsusceptibility rates to levofloxacin.
Methods. Nonrestrictive antimicrobial stewardship interventions included monitoring and reporting of fluoroquinolone
susceptibility trends to physician groups, performing medication use evaluations of levofloxacin accompanied with prescriber
detailing, daily prospective audit and feedback, implementation of beta-lactam-based institutional guidelines for empiric therapy
in various infectious disease syndromes, review and adjustment of electronic medical record order sets containing
fluoroquinolones, and intensive prescriber education. No preauthorization of levofloxacin was used during this study period.
Antibiotic utilization data were collected for the time periods of August 2015 through January 2021. Correlation between
levofloxacin and other broad-spectrum antibiotc use was investigated as well as the impact on Pseudomonas aeruginosa
levofloxacin nonsusceptibility rates.
Results. Both hospitals showed an overall downward trend in the prescribing of levofloxacin during the time period of August
2015 to January 2021. There was a significant negative correlation between monthly ceftriaxone and levofloxacin days of therapy for
both hospitals (P < .0001). There was a positive correlation between levofloxacin days of therapy and P aeruginosa nonsusceptibility
(P < .02 at both hospitals).
Conclusions. Our results demonstrate that a nonrestrictive approach to fluoroquinolone stewardship interventions had a
significant impact on reducing levofloxacin utilization, increasing ceftriaxone utilization, and improving P aeruginosa
levofloxacin susceptibility.
Keywords. fluoroquinolone stewardship; antibiotic stewardship; antimicrobial stewardship program; antimicrobial resistance;
levofloxacin.

Fluoroquinolones (FQ) are broad-spectrum antibiotics that
have been increasingly used in both the inpatient and outpa
tient settings over the last 2 decades [1, 2]. Levofloxacin
(LVX) specifically is one of the most commonly used antimi
crobials in the United States [3]. Its high bioavailability,
once-daily dosing, and broad activity against enteric and respi
ratory pathogens, including Pseudomonas aeruginosa, make it
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an appealing anti-infective in various treatment settings.
These attributes coupled with its availability as an oral formu
lation has led to overutilization in both the inpatient and out
patient settings [4]. This has resulted in diminished
effectiveness as an empiric therapy for urinary tract and intraabdominal infections due to the increasing emergence of resis
tance among pathogens commonly causing these infections. To
date, hospital and community resistance rates of Escherichia
coli and P aeruginosa to FQ have been increasing [2, 5, 6].
Currently, per the US Food and Drug Administration (FDA)
and various national treatment guidelines, alternative agents
are recommended in urinary tract and upper respiratory tract
infections due to increased pathogen resistance and associated
adverse drug reactions [7]. Fluoroquinolones as a class are as
sociated with several toxicities, with a spectrum of reactions in
cluding cardiotoxic effects, central nervous system effects,
photosensitivity, tendinopathies, and glycemic disturbances
[8, 9]. Due to these concerns, in 2016 the FDA issued a warning
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METHODS

This study took place at Hoag Hospital (HH) and Providence
St. Joseph Hospital of Orange (PSJH) from August 2015 to
January 2021 and was approved by each respective institutional
review boards. Both institutions are nonacademic community
hospitals each consisting of more than 450 beds in the greater
Los Angeles metropolitan area of Southern California.
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Antimicrobial Stewardship Interventions

In January 2017, both institutions formally initiated a nonre
strictive approach to antimicrobial stewardship with the goal
of decreasing LVX use. The bundle of interventions was based
on certain action elements of the 2019 Centers for Disease
Control and Prevention Core Elements of Hospital Antibiotic
Stewardship Programs. The primary method consisted of pre
scriber education at both institutions provided by antimicrobi
al stewardship program personnel through various physician
group meetings. Education in the form of in-person presenta
tions included the risks associated with FQ use and providing
FQ-sparing recommendations for infections where FQs were
known to be frequently used. This included the substitution
of (1) LVX plus metronidazole with ceftriaxone (CRO) plus
metronidazole as empiric therapy for most intra-abdominal in
fections and (2) CRO plus azithromycin instead of LVX for
community-acquired pneumonia. Fluoroquinolone suscepti
bility trends were regularly monitored and reported to various
physician groups. Medication use evaluations were conducted
to determine for which infectious disease syndromes LVX
was mostly prescribed and the distribution of LVX prescribing
among different provider specialties. Anonymous peer com
parison reports of LVX prescribing were shared with providers
to enable individualized feedback. Changes to institutional
treatment guidelines and sepsis order sets were conducted to
remove or place LVX lower in the antibiotic selection list. In sit
uations in which there was a concern and a need for double
coverage of P aeruginosa due to low susceptibilities of select
beta-lactams, aminoglycosides were recommended in place of
LVX due to its lower resistance rates among P aeruginosa.
Both institutions conducted daily prospective audit and feed
back of LVX use by infectious diseases and clinical pharmacists.
No preauthorization of LVX was used during this study period;
thus, any provider was able to prescribe LVX at each respective
hospital. For PSJH, education provided to physician groups oc
curred biannually from 2017 to 2018. Reporting of provider
peer comparison of LVX prescribing occurred in 2017 and
2019. Electronic medical record order sets and treatment
guidelines were updated in 2019. Routine prospective audit
and feedback was performed since January 2017 and through
out the study period. At HH, educational quarterly meetings
occurred from 2017 to 2019 at hospitalist, intensivist, and anti
microbial stewardship committee meetings. These meetings
also provided peer comparisons of prescribers’ LVX use.
Order-set and institutional guideline changes occurred from
September 2016 to March 2017. Prospective audit and feedback
was performed from 2017 and throughout the study period.
Antibiotic Use and Resistance Rates

Antibiotic utilization data were collected for the time periods of
August 2015 through January 2021 using monthly days of ther
apy (DOT) per 1000 patient-days (PD) as the metric. Data for
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stating that FQ should only be used if no alternative agents are
appropriate for the treatment of acute bronchitis, uncomplicat
ed urinary tract infection, and acute sinusitis, due to the poten
tial risks outweighing the benefits of FQ use for these
indications. In addition, FQ have been found to have direct
and “collateral” effects on resistance, including development
of resistance to other classes of antibiotics such as carbapenems
[10]. Furthermore, their usage has been associated with
Clostridioides difficile and methicillin-resistant Staphylococcus
aureus infections [11–13].
Based on the high FQ resistance among common organisms,
their association with C difficile infection, and documented ad
verse drug reactions, we developed strategies to curb the exces
sive use of LVX in our institutions that did not involve LVX
preauthorization. A restrictive intervention involving antibiot
ic preauthorization has been shown to significantly decrease
antibiotic usage, but this has important disadvantages [14–18].
These disadvantages include loss of prescriber autonomy,
real-time resource intensive, and potential for manipulation
of the restricted antibiotic approval system to gain prescrip
tion access [19]. On the contrary, nonrestrictive approaches
to reduce inappropriate antibiotic use have been described
in the literature, but these methods are relatively scarce in
comparison to restriction methods. The nonrestrictive strate
gies described have included prospective audit and feedback
to decrease total antibiotic use with sustained reduction
over the period of years as well as modifications of local clin
ical guidelines and intensive prescriber education [20, 21].
Specific nonrestrictive interventions that we used included
the following: monitoring and reporting FQ susceptibility
trends to physician groups, performing medication use evalu
ations of LVX accompanied with prescriber detailing, daily
prospective audit and feedback, implementation of
beta-lactam-based institutional guidelines for empiric thera
py in various infectious disease syndromes, review and adjust
ment of electronic medical record (EMR) order sets
containing FQ, and intensive prescriber education. No preau
thorization of LVX was used during this study period.
In this study, we describe the impact of nonrestrictive anti
microbial stewardship interventions targeting LVX use in 2
nonacademic community hospitals, specifically its effect on
LVX prescribing patterns, alternative antibiotic utilization,
and inpatient collected P aeruginosa nonsusceptibility rates.

Statistical Analysis

Statistical analysis was performed using GraphPad version 6.0
and R statistical computing software version 3.6.1. Correlation
analysis was performed by Spearman correlation test. An inter
rupted time-series analysis was used to examine the pattern in
the utilization of LVX [23, 24]. Data from both hospitals were
assessed and adjusted for seasonality. The interrupted
time-series regression included both times, the intervention,
and the interaction of time and intervention as independent var
iables. This analysis assesses whether there was an overall trend,
whether mean levels of LVX were the same before and after the
intervention, and whether there was a change in trend at the
point of intervention indicated by a significant slope change.
Finally, Pettitt’s test was used to determine whether the data
supported a statistically significant trend change point
RESULTS

Both HH and PSJH showed an overall downward trend in the
prescribing of LVX during the time period of August 2015 to
January 2021. In August 2015, HH used 62 DOT/1000 PD of
LVX, and by January 2021 the reported DOT/1000 PD was
8. In August 2015, PSJH used 100 DOT/1000 PD of LVX, and
by January 2021 use was at 20 DOT/1000 PD. Overall unadjust
ed LVX and other broad-spectrum antibiotic use for each hos
pital over the study period are depicted in Figure 1A and B. Of
note, ciprofloxacin and ceftazidime are nonformulary at HH
and PSJH, respectively. The seasonally adjusted monthly use
is depicted in Figure 1C and D for each hospital.
The interrupted time-series regression with seasonally ad
justed data was significant for time (months) for both HH

and PSJH (P < .0001 and P < .01, respectively), indicating that
both hospitals showed an overall downward trend in the rate
of use. Average LVX usage was less after the intervention for
both hospitals (P < .0001 and P < .01, respectively). The inter
action of time and intervention was significant only for HH
where there was a slope change at the intervention point of
January 2017, in which the slope before intervention was
−1.99 and −0.49 after (Figure 1E). Thus, for HH, there was a
more dramatic decrease in LVX use before the formal com
mencement of the LVX stewardship initiative, compared with
the timeframe thereafter. No statistically significant change in
slope was identified for PSJH because the slope showed a con
tinuous decline over the timeframe (Figure 1F). Pettitt’s test re
vealed significant trend changes for both HH and PSJH (P <
.0001 and P < .0001, respectively); however, these points were
after the intervention point of January 2017. The test indicated
a trend change at the time point of March 2018 for HH and at
the time point of May 2018 for PSJH. Both points were after the
intervention point, which indicated that the downward trend
continued until finding a stable utilization rate.
As mentioned above, both hospitals observed an overall de
crease in FQ use over the August 2015 to January 2021 time
frame. Reviewing DOT/1000 PD data graphically along with
other broad-spectrum antibiotics, we noted that CRO use
tracked in the opposite direction of LVX. Therefore, LVX and
CRO DOT data were tested for correlation using Spearman
correlation analysis for HH, because the data was not normally
distributed, and Pearson correlation analysis for PSJH. There
was a significant negative correlation between monthly CRO
and LVX DOT for both hospitals; as LVX DOT decreased,
CRO DOT increased (P < .0001). This correlation was consistent
when performing an analysis of 3-month and 6-month data of
CRO and LVX DOT for HH and PSJH (P < .0001) (Figure 2).
Correlation analysis of LVX and other broad-spectrum antibiot
ics depicted in Figure 1A and B was also performed, and it was
demonstrated that CRO was the antibiotic with the strongest
correlation with LVX (Table 1).
There was a positive correlation between LVX DOT and P
aeruginosa nonsusceptibility to LVX in which the percentage
of nonsusceptible isolates over a 6-month timeframe decreased
as LVX DOT decreased at each hospital (P = .0161 and P =
.0068, for HH and PSJH, respectively). Furthermore, after ana
lyzing the nonsusceptibility and DOT data on a 3-month basis,
we noted there was also a significant positive correlation during
this timeframe for each hospital (P = .0067 and P = .0132, for
HH and PSJH, respectively) (Figure 3).

DISCUSSION

In this study, 2 separate community hospitals implemented the
same goal and approaches to reducing LVX use. The initial
drive for establishing an antimicrobial stewardship goal of
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monthly use of LVX and CRO were obtained from the same
sources at both institutions in an effort to minimize deviations
in reported patient-days or antibiotic use. Utilizing hospital
EMR surveillance systems, antibiogram data including suscept
ibility rates of P aeruginosa were collected for the time period of
August 2015 through January 2019. Nonsusceptibility to LVX
was calculated based on the number of P aeruginosa isolates
collected from inpatient locations that were either resistant or
intermediate to LVX. Susceptibility results were specific for or
ganisms isolated from inpatient hospital locations, with emer
gency department collected strains excluded. All susceptibility
data at both institutions were collected before implementation
of the recommended Clinical and Laboratory Standards
Institute (CLSI) LVX minimum inhibitory concentration
breakpoint update publicized in February 2019 [22]. Due to
changes in the CLSI minimum inhibitory concentration break
points for LVX, which were implemented by both hospitals,
and additional changes in cascading practices by one of the hos
pital’s microbiology laboratories, consistent data on LVX sus
ceptibility was only available through January 2019.

reducing LVX use at each institution was due to the high LVX
resistance rates among Enterobacterales and P aeruginosa,
which made them poor empiric therapeutic choices for
Gram-negative infections, and the risk of FQ-associated tox
icities. Both institutions were successful in decreasing LVX
use as indicated by the time-series regression demonstrating
an overall downward trend and the average LVX usage being
less after the intervention. The decrease in LVX use was sus
tained over a 4-year period and continues to this day (data
not shown). This was achieved through nonrestrictive ap
proaches targeting prescribing behaviors primarily through
prescriber education, prospective audit and feedback, and
4 • OFID • Truong et al

modifications to institutional antibiotic recommendations,
among other various interventions. Although both institu
tions formally initiated the goal of decreasing LVX use in
2017, HH’s LVX use had already began to decline in the sum
mer of 2016, likely due to the issued FDA warning regarding
FQ use in May 2016. This resulted in 2 different slopes that
were significantly different in which the first slope had a
steeper decrease compared to the second slope, which was
less steep and essentially flat, indicating that LVX prescribing
had plateaued (Figure 1E). Providence St. Joseph Hospital of
Orange had 1 slope that demonstrated a continuous decrease
over the timeframe (Figure 1F).
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Figure 1. Broad-spectrum antibiotic (ABX) days of therapy (DOT)/1000 patient-days (PD) by every 6 months: (A) Hoag Hospital (HH); (B) Providence St. Joseph Hospital of
Orange (PSJH). Seasonally adjusted levofloxacin (LVX) DOT/1000 PD by month and year: (C) HH; (D) PSJH. LVX DOT/1000 PD with trend lines are depicted in (E) and (F ) for
HH and PSJH, respectively.

Furthermore, as LVX use decreased, we found a significant
correlation with increased use of CRO (Figure 2). This was ex
pected because many of our institutional guidelines and order
sets replaced LVX with CRO due to its higher susceptibility rates
among Enterobacterales. Prescriber education on utilizing betalactam antibiotic alternatives further shifted provider prescrib
ing behavior away from LVX. This phenomenon has been
referred to in the literature as “squeezing the balloon”—
noteworthy because both LVX and CRO are known to add
selective pressure for extended-spectrum beta-lactamase
(ESBL)-producing organisms [25–27]. Nevertheless, FQs as a
class have been implicated in serious and sometimes debilitating
adverse drug reactions not seen with beta-lactam antibiotics.
Based on the superior susceptibility profile of CRO compared
with LVX among the Enterobacterales organisms, empiric treat
ment with CRO when these organisms are suspected is crucial
for optimizing patient outcomes.
The nonrestrictive approach used by our institutions has
been described for various antibiotic classes, including FQ;
however, the available published literature on this approach
is relatively scarce in comparison to restriction methods
[20, 21, 28]. Numerous studies have previously described success
ful reduction in FQ prescribing through preauthorization in
which FQ were restricted to qualified prescribers, certain diseases
states, or required approval from antimicrobial stewardship
personnel [14–17, 29]. Antimicrobial stewardship programs
utilizing this restriction approach have been largely successful

in decreasing FQ utilization and have had significant positive
impacts on associated outcomes such as C difficile infection
rates, FQ resistance rates, and burden of ESBL-producing or
ganisms [13, 14, 30, 31]. The restrictive approach to decreasing
targeted antimicrobial use can be more rapid compared to non
restrictive approaches; however, due to the perceived negative
connotation with this approach, our institutional antimicrobial
stewardship programs chose alternative interventions to chan
ge prescribing behavior with less of a perceived negative conno
tation among prescribers. Although nonrestrictive approaches
are thought to be more labor intensive and time consuming
particularly before an impact is observed, we saw decreases in
LVX prescribing in the months after the formal implementa
tion of this antimicrobial stewardship initiative.
At each of our institutions, LVX susceptibility among E coli
and P aeruginosa were approximately 70%. There have been a
number of studies that demonstrated correlation between FQ
use and FQ nonsusceptibility among P aeruginosa and E coli,
in which decreases of FQ use within the hospital and commu
nity settings resulted in decreases in FQ nonsusceptibility in
these organisms [6, 14, 30, 32]. Likewise, in our study, we found
a positive correlation between LVX use and LVX nonsuscepti
bility in P aeruginosa, where decreases in LVX correlated with a
decrease in nonsusceptible P aeruginosa organism isolation.
We cannot say that this correlation was solely due to decreases
in inpatient LVX use, because it is possible that decreases in FQ
use within the community setting could have also contributed.
Nonrestrictive Fluoroquinolone Stewardship • OFID • 5
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Figure 2. Correlation analysis of levofloxacin (LVX) and ceftriaxone (CRO) days of therapy (DOT)/1000 patient-days (PD) by months, 3 months, and 6 months at (A) Hoag
Hospital (HH); (B) Providence St. Joseph Hospital of Orange (PSJH).

Table 1. Correlation Analysis of LVX Versus Other Broad-Spectrum Antibioticsa
Hospital

Broad-Spectrum Antibiotics

HH

FEP

CAZ/CIP*

CRO

MEM

TZP

r

−0.6135

−0.865

0.8453

−0.9863

0.7506

0.5123

r2

0.376

0.748

0.715

0.973

0.563

0.263

P Value

.484

.0011

.0018

<.0001

.01

.1318

SAM

FEP

CIP

CRO

MEM

TZP

r

−0.5247

−0.8753

0.6692

−0.9534

−0.6525

−0.1032

r2

0.275

0.7662

0.4478

0.9090

0.4257

0.0107

P Value

.0975

.0004

.0243

<.0001

.0295

.7626

PSJH

Abbreviations: CAZ, ceftazidime; CIP, ciprofloxacin; CRO, ceftriaxone; FEP, cefepime; HH, Hoag Hospital; LVX, levofloxacin; MEM, meropenem; PSJH, Providence St. Joseph Hospital of
Orange; SAM, ampicillin-sulbactam; TZP, piperacillin-tazobactam.
a

Spearman correlation was used for HH data, and Pearson was used for PSJH. *CIP is formulary only at PSJH, and CAZ is formulary only at HH.

Figure 3. Correlation analysis of Pseudomonas aeruginosa (PSA) levofloxacin (LVX) nonsusceptibility (non-S) and LVX days of therapy (DOT)/1000 patient-days (PD) data on
a 3-month basis for (A) Hoag Hospital (HH) and (B) Providence St. Joseph Hospital of Orange (PSJH) and on a 6-months basis for (C) HH and (D ) PSJH.

6 • OFID • Truong et al

Downloaded from https://academic.oup.com/ofid/article/9/8/ofac388/6652982 by Chapman University Library user on 25 August 2022

SAM

CONCLUSIONS

We demonstrated that a nonrestrictive antimicrobial steward
ship approach to decreasing LVX use resulted in increased
CRO utilization and a decrease in LVX nonsusceptible P aerugi
nosa organisms. We speculate the decrease in LVX may result in
less adverse drug reactions, along with a higher likelihood of

achieving active empiric antimicrobial therapy due in part to
CRO’s superior susceptibility rates among the Enterobacterales
organisms, coupled with a demonstrated improvement in LVX
susceptibility among inpatient P aeruginosa isolates. This was ac
complished by targeting prescribing behaviors and the provision
of provider feedback and education, which may have less of a
negative connotation compared to restrictive approaches.
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Recent reports show that community FQ prescribing has de
creased after previous FDA warnings on FQ use [33, 34].
Although we tried to minimize this potential impact by includ
ing organisms isolated from inpatient locations only and
excluded outpatient and emergency department locations,
it is still possible that community FQ prescribing may have
contributed.
Furthermore, antibiogram susceptibility data were used to
determine P aeruginosa resistance to LVX, which has potential
limitations [35]. The antibiogram evaluated at each hospital
may underestimate the true nonsusceptibility rates; because
antibiogram susceptibility data are developed from the CLSI
M39 standard of including only the first isolate from a patient
within a calendar year, susceptibility data from subsequent iso
lates in each patient may have demonstrated nonsusceptibility
to LVX within a designated time period [36]. Despite that the
hospital-wide antibiogram included isolates from inpatient cul
tures only, a portion of isolates collected close to the time of
hospital admission may have resistance phenotypes beyond
the influence of our inpatient stewardship interventions [35, 37].
However, antibiogram evaluation was the method used for
gauging antibiotic susceptibility rates in both of our respective
hospitals and was used for selecting empiric antibiotic
regimens. Moreover, the effect of our stewardship efforts on
E coli and Klebsiella pneumoniae susceptibility rates to LVX
was not assessed due to FQ susceptibility result suppression
rules applied at HH for enteric Gram-negative isolates.
Fluoroquinolone susceptibility results were not reported in
the EMR if the isolate proved to be susceptible, and results
were only displayed if the organism was resistant to LVX, pre
venting accurate analysis of susceptibility rates because sup
pressed results could not be calculated in the overall rate. Use
of ciprofloxacin was not analyzed because its use was not tar
geted due to its exclusion from HH’s drug formulary and low
baseline use at PSJH. Of note, ciprofloxacin DOT/1000 patientdays remained consistent throughout the study time period at
PSJH (Figure 1B). Hospital-onset C difficile rates decreased at
both hospitals during the postintervention period; however,
analyses were not conducted for this study due to multiple con
founders potentially contributing to the decreased C difficile
rates. These potential confounders included changes in testing
methodology, routine probiotic use in patients on broad spec
trum antibiotics, and increase in infection prevention measures
and outreach.
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